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Abstract 
 
The two cardinal pathologies of Alzheimer’s disease (AD) develop according to distinct 
anatomical trajectories. Cerebral tau-related pathology first accumulates in the mesial 
temporal region, while amyloid-related pathology first appears in neocortex. The eventual 
distributions of these pathologies reflect their anatomical origins. An implication is that the 
cardinal pathologies might exert preferential effects on the structurofunctional brain 
changes observed in AD. We investigated this hypothesis in 39 patients with dementia of 
the Alzheimer’s type. Interrelationships were analysed between cerebrospinal fluid (CSF) 
biomarkers of the cardinal pathologies, volumetric brain changes using magnetic resonance 
imaging, and brain metabolism using [18F]-FDG-PET. Amyloid-related pathology was 
preferentially associated with structurofunctional changes in the precuneus and lateral 
temporal regions. Tau-related pathology was not associated with changes in these regions. 
These findings support the hypothesis that tau- and amyloid-pathology exert differential 
effects on structurofunctional changes in the AD brain. These findings have implications 
for future therapeutic trials and hint at a more complex relationship between the cardinal 
pathologies and disruption of brain networks.   
 
Keywords: Alzheimer’s, P-tau, beta-amyloid, cerebrospinal fluid, cortical thickness, 
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Introduction 
Alzheimer’s disease (AD) is characterised by two cardinal pathologies, namely the 
intracellular accumulation of tau-related neurofibrillary tangles (NFTs), and the 
accumulation of various soluble and insoluble extracellular amyloid-beta (Aβ) aggregates. 
In typical AD, the genesis of these pathologies follows well-described anatomical 
trajectories. The formation of cerebral tau-related pathology begins in the entorhinal cortex, 
then spreads to nearby limbic regions (including the hippocampus) before infiltrating broad 
regions of isocortex [1]. In contrast, the formation of amyloid-related pathology begins in 
basal isocortex before spreading inwards to mesial temporal structures and finally involving 
more diffuse isocortical regions [2]. Several in vivo imaging studies have revealed greatest 
Aβ binding in anterior neocortex, with relatively little uptake in mesial temporal structures 
[3-5]. 
 
The different anatomical distribution of tau- and amyloid-pathology raise the question of 
whether they preferentially relate to structurofunctional changes in the AD brain. We have 
previously hypothesised that tau-pathology is preferentially associated with changes in the 
mesial temporal regions, while amyloid pathology is preferentially associated with diffuse 
neocortical changes [6, 7]. The aim of this study was to investigate this hypothesis using 
volumetric measurements obtained via structural magnetic resonance imaging and relative 
cerebral metabolism assessed with [18F]-FDG-PET. These modalities have been 
demonstrated to be sensitive to the pathological processes of AD [8]. Cerebrospinal fluid 
(CSF) protein markers of AD pathology were used as measures of the cardinal pathologies, 
as they present the only widely available method of measuring P-tau and Aβ pathological 
load in vivo using a common modality [9, 10]. 
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Here we report an investigation of this preferential association hypothesis in a cohort of 
patients with dementia of the Alzheimer’s type (DAT). We expected to find differential 
relationships between CSF biomarkers and regional structurofunctional changes in AD. 
Specifically, CSF levels of P-tau were expected to be preferentially associated with 
structurofunctional changes in the mesial temporal structures. Levels of Aβ in CSF were 
expected to be preferentially associated with structurofunctional changes in neocortex. 
 
Material and Methods 
Participants 
Participants were 39 patients (22 males, 17 females) with DAT, diagnosed according to 
National Institute on Aging – Alzheimer's Association criteria [11]. All were recruited from 
clinical sources in Melbourne, Australia. Ethics approval was obtained from the 
institutional ethics committee (Melbourne Health, HREC 2012.148) and all patients gave 
written informed consent. We have reported resting-state fMRI findings from this cohort 
elsewhere [7].  
 
CSF Biomarkers 
CSF biomarkers were sampled via lumbar puncture, aliquoted and stored at -80°C pending 
analyses. CSF Aβ1-42 levels were determined using a sandwich ELISA method 
(INNOTEST® ß- AMYLOID(1-42), Innogenetics, Gent, Belgium), as previously described 
[12]. CSF total tau (T-tau) concentrations was determined using a sandwich ELISA 
(Innotest hTAU-Ag, Innogenetics, Gent, Belgium) specifically constructed to measure all 
tau isoforms irrespectively of phosphorylation status [13], while CSF P-tau (phosphorylated 
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at threonine 181) was measured using a sandwich ELISA method (INNOTEST® 
PHOSPHO-TAU(181P), Innogenetics, Ghent, Belgium), as described previously in detail 
[14]. Cut-offs for the analyses were 530 pg/mL for Aβ1-42, 350 pg/mL for T-tau and 60 
pg/mL for P-tau [15]. All CSF measurements were performed in one round of experiments 
using one batch of reagents, by board-certified laboratory technicians, who were blinded to 
clinical data. Internal quality control (QC) samples were run on each plate to assure 
consistency. Intra-assay coefficients of variation were < 11.1% for Aβ1-42, <13.3% for T-
tau and <9.2% for P-tau. 
 
Image Acquisition 
Structural images were acquired on a 3.0T Siemens Tim Trio scanner at the Royal 
Melbourne Hospital, Melbourne, Australia. Structural images comprised a 176-slice sagittal 
3D acquisition (MPRAGE; flip angle = 9°, TR = 1900 ms, TE = 2.13 ms, TI = 900 ms, 
FOV = 176 x 256, matrix = 256 x 256; slice thickness = 1 mm). All image volumes were 
inspected at the time of acquisition, with acquisition repeated were necessary (e.g., due to 
gross movement artefact). 
 
[18F]-FDG-PET images were acquired at the PET Centre at the Peter MacCallum Cancer 
Centre in Melbourne. After a minimum of 6 hours fasting, patients were instructed to lie 
quietly in a darkened room for 15 mins. Patients were then injected with 220 MBq of 
fluorodeoxyglucose ([18F]-FDG-PET) through an intravenous catheter and continued 
resting for at least 45 mins. After resting the patients were scanned on a GE Discovery 690 
(GE Medical Systems Milwaukee, WI). Patients were positioned supine with their heads 
secured in a dedicated head-rest. A low dose CT scan for attenuation correction was 
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acquired with the following exposure parameters, 120kV, Auto mA range 40-80, rotation 
time of 0.5 sec, pitch 0.984, slice thickness 3.75 mm. A 15-minute list-mode PET 
acquisition of the brain was then acquired and re-framed into a dynamic scan of 15 x 1 
minute frames to detect any patient motion. Frames with motion present were excluded 
from processing. All PET scans were processed without time-of-flight using OSEM3D 
iterative reconstruction using 8 iterations, 24 subsets, 5 mm filter, 192 matrix and a 35 cm 
field of view. Images were inspected following acquisition to ensure no gross artifact (i.e., 
movement) rendered them unusable. 
 
Image Processing 
Cortical thickness analysis was using the Freesurfer software package (version: 5.2.0), the 
full technical details of which are described elsewhere [16]. The resulting cortical models 
were visually inspected by an experience operator (CBM) to ensure accuracy. Manual 
corrections to the brain mask were made where non-cortical tissue had been included in the 
cortical model. Six regions of interest were specified in order to extract mean thickness 
estimates from the cortical model. These included (a) pre-frontal cortex, (b) orbitofrontal 
cortex, (c) precuneus, (d) lateral-temporal cortex, (e) anterior-cingulate cortex, and (f) 
entorhinal cortex. These regions have been previously identified as containing high 
amyloid-load using in vivo PET imaging [17]. The anterior cingulate was included 
following previous work from our group implicating this region in amyloid-beta load [7]. 
The specific ROIs (and their FreeSurfer labels) for each region are shown in Figure 1. 
Cortical thickness estimates were averaged across ROIs and also across hemispheres, 
resulting in a single mean thickness estimate for each region. For the hippocampus, the 
estimated volume was extracted from the FreeSurfer sub-cortical pipeline and averaged 
- 7 - 
across hemispheres. 
 
The [18F]-FDG-PET images were aligned to FreeSurfer structural space using a linear 
boundary-based registration approach [18]. Briefly, this involves segmenting the structural 
reference image into tissue classes and coregistering the FDG-PET image by maximizing 
the intensity gradient across tissue boundaries. The transformation matrices were then used 
to inversely register the FreeSurfer ROIs to native [18F]-FDG-PET space. In this way, the 
[18F]-FDG-PET volumes were not subjected to potential degradation associated with 
manipulation or interpolation. Mean [18F]-FDG-PET uptake was extracted from each of the 
six cortical regions and the hippocampus as described above. In addition, the mean uptake 
for the entire cerebellum was extracted. Normalised mean uptake for each ROI was then 
calculated by dividing by the mean uptake for the cerebellum. 
 
Statistical Analysis 
All analyses were performed in SPSS v24.0.0 (IBM Corporation). The relationship between 
CSF biomarkers and imaging metrics was analysed using Pearson’s partial correlation 
coefficients. For [18F]-FDG-PET, mean uptake in each of the seven regions was correlated 
with each of the three biomarkers, adjusted for age. For the structural analyses, mean 
cortical thickness for the six pial regions, and the volume of the hippocampus, were 
correlated with the three biomarkers adjusting for age and intracranial volume (ICV). ICV 
was computed using the default procedure implemented in FreeSurfer. Briefly, this 
procedure estimates ICV by exploiting the known relationship between true intracranial 
volumes and the determinant of transform matrix produced by normalizing the whole-brain 
T1 image to MNI305 space. As described in Buckner and colleagues [19], this approach 
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has been validated against manually segmented intracranial volume and is minimally biased 
in populations with dementia.   
 
This resulted in 42 statistical comparisons. Given the increased risk of type 1 error, the 
Benjamini-Hochberg procedure was used to control the false discovery rate (FDR) at 5% 
[20]. FDR correct p-values below .05 were considered statistically significant. In order to 
show a true statistical dissociation (i.e., an interaction), it is necessary to demonstrate that 
the two correlation coefficients are statistically significantly different from one another, not 
merely that one is statistically significantly different from zero and the other is not [21]. In 
order to achieve this, where a statistically significant region was found the correlation 
between it and Aβ was compared to the correlation with P-tau using an approach described 
elsewhere for dependent correlation coefficients [22]. Statistically significant correlations 
were subjected to sensitivity analysis to determine the effect of Aβ status. Specifically, the 
sample was split into those with ‘normal’ versus ‘abnormal’ CSF Aβ1-42 concentrations 
(defined as Aβ1-42 < 530 pg/mL, as described above). Correlation coefficients were then 
computed for the ‘abnormal’ sub-sample in isolation.  
 
Results 
Descriptive Statistics 
Descriptive data for the study sample are shown in Table 1.  
 
Cortical Thickness 
As shown in Figure 2, mean cortical thickness in the precuneus was positively associated 
with CSF levels of Aβ1-42, r = .49, p = .01. There was no statistically significant 
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relationship with P-tau, r = -.14, p = .91. The difference between these correlation 
coefficients was statistically significant, t(36) = 2.97, p = .005. A similar pattern was 
observed in the lateral temporal region. Mean cortical thickness was positively correlated 
with CSF Aβ1-42 concentration, r = .49, p = .01, but there was no statistically significant 
correlation with P-tau, r = -.11, p = .86. The difference between these correlation 
coefficients was statistical significance, t(36) = 2.82, p = .008. As shown in Figure 4, no 
statistically significant associations emerged for T-tau.  
 
[18F]-FDG-PET  
Only two regions showed statistically significant correlations with the CSF biomarkers. 
These results are shown in Figure 3. Uptake in the precuneus was positively correlated with 
levels of Aβ1-42, r = .44, p = .02. The correlation with P-tau did not reach significance, r = 
-.07, p = .97. The difference between these correlation coefficients was statistically 
significant, t(36) = 2.32, p = .03. The correlation between the Aβ1-42 and FDG uptake in 
the lateral temporal region was also positive and statistically significant, r = .44, p = .02. 
The correlation with P-tau and uptake in this region did not reach significance, r = -.01, p = 
.97. Again, the difference between these coefficients was statistically significant, t(36)= 
2.09, p = .04. As shown in Figure 4, no statistically significant associations emerged for T-
tau (all ps > .05). 
 
Effect of CSF Aβ1-42 status 
Twenty-nine participants (74%) had abnormal CSF Aβ1-42 concentrations. Despite the 
smaller sample size, the correlation between Aβ1-42 and FDG uptake in the precuneus 
remained statistically significant, r = .46, p = .013. The correlation between Aβ1-42 and 
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FDG uptake in the lateral temporal regions, however, was no longer statistical significance, 
r = .14, p = .48. The correlation between CSF Aβ1-42 and cortical thickness in the 
precuneus was slightly reduced in the sub-sample and no longer, r = .33, p = .10. A similar 
pattern was observed for thickness in the lateral temporal regions, r = .21, p = .28. No 
correlations between CSF P-tau and neuroimaging markers in the sub-sample.  
 
Discussion 
The findings of this study partially support a preferential association between AD 
biomarkers and structurofunctional changes in patients with DAT. As expected, levels of 
Aβ-related pathology were associated with [18F]-FDG-PET uptake and cortical thickness in 
the precuneus and lateral temporal regions. While reduced glucose metabolism and cortical 
thickness in these regions was associated with greater levels of Aβ-related pathology, there 
was no detectable relationship with tau-related pathology. These differential relationships 
were statistically supported. As the precuneus and lateral temporal regions are amongst 
those with greatest Aβ accumulation in AD, these preferential associations are consistent 
with the hypothesis discussed here. No other regions showed detectable inter-relationships 
between [18F]-FDG-PET uptake, cortical thickness, and disease biomarkers.  
 
Our findings are partially consistent with previous reports. For example, Vukovich and 
colleagues also reported a positive association between CSF Aβ and glucose metabolism in 
the right temporal region [23]. As with our study, no relationships were found between 
glucose metabolism and CSF T-tau. Statistical relationships were, however, reported 
between CSF Aβ, prefrontal, and anterior cingulate hypometabolism. Chiaravalloti and 
colleagues also investigated the FDG-PET correlates of CSF biomarkers in Alzheimer’s 
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disease [24]. Higher CSF P-tau and T-tau was associated with reduced uptake in frontal and 
limbic regions. CSF Aβ was associated with wide-spread cortical dysfunction. While the 
existence of differential relationships between the biomarkers is broadly consistent with our 
hypothesis, the regions reported are not consistent with the regions revealed by our study.  
 
In terms of structural imaging studies, our findings are again partially consistent with 
previous reports in the literature. For example, Ossenkoppele and colleagues [25] found a 
correlation between CSF Aβ and atrophy in the precuneus. Our lack of statistically 
significant results in the medial temporal regions is not consistent with a body of evidence 
that CSF biomarkers are related to morphometric variability in the limbic regions, including 
the hippocampus [26, 27]. Our general finding of a dissociation between P-tau and other 
CSF biomarkers, however, is consistent with previous research showing preferential 
relationships between P-tau and brain atrophy assessed via MRI [28-30].  
 
The preferential associations between biomarkers and structurofunctional change in the 
precuneus are consistent with the known distribution of AD pathology. The precuneus is 
the region of cortex occupying the medial aspect of the superior parietal lobule and lies 
adjacent to the posterior cingulate cortex [31]. Together, the precuneus and posterior 
cingulate regions are sites of early Aβ accumulation [32]. In contrast, the formation of tau-
related pathology in this region occurs later in the pathogenesis of the disease [1, 33]. A 
number of in vivo imaging studies have confirmed the precuneus and posterior cingulate 
region as having affinity for Aβ ligands in patients with DAT and MCI [34, 35]. Imaging 
investigations in patients with DAT have revealed hypometabolism, hypoperfusion, 
structural atrophy, and abnormal functional connectivity in this combined region [36]. 
- 12 - 
 
There is evidence to suggest two possible mechanisms of structurofunctional change in the 
precuneus and posterior cingulate region. Specifically, such changes may relate to local Aβ 
accumulation, or they may occur secondarily to disconnection from the mesial temporal 
region. The first mechanism, that changes in the precuneus and posterior cingulate regions 
may be secondary to local Aβ deposition, is consistent with the direct pathway of Aβ 
toxicity implicated in the amyloid cascade hypothesis [37]. A number of studies have 
reported that Aβ oligomers directly disrupt synaptic function, supporting the view that local 
Aβ deposition in cortical regions may result in local synaptic disruption, eventually leading 
to structurofunctional changes [38, 39]. A recent imaging study has confirmed the 
relationship between local Aβ deposition and structural atrophy, but only in regions of 
greatest Aβ deposition, including the precuneus and posterior cingulate [40]. There is also 
evidence that Aβ deposition precedes hypometabolism in the precuneus and posterior 
cingulate region, further supporting a relationship between local Aβ deposition and local 
structurofunctional change [41].    
 
Secondary disconnection from mesial temporal regions is the second possible mechanism 
of structurofunctional change in the precuneus and posterior cingulate region. This 
hypothesis is supported by reports that the relative degree of hypometabolism exceeds the 
degree of structural atrophy in the precuneus and posterior cingulate region [42]. An 
implication of this discrepancy is that local structural atrophy in this region may be 
insufficient to explain the degree of hypometabolism, suggesting an additional contribution. 
A candidate for this additional contribution is that hippocampal atrophy induces a 
progressive breakdown of cingulum fibres, which then leads to precuneus and posterior 
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cingulate hypometabolism [43]. In this sense, Wallerian degeneration might be an 
additional cause of hypometabolism and structural atrophy observed in this region [44].  
 
It is still unclear as to whether the two mechanisms described above are equally 
contributory, or whether one or the other predominates at different stages of the disease. 
While the present finding of a relationship between Aβ-related (but not P-tau related) 
pathology and structurofunctional changes in the precuneus does not conclusively resolve 
this issue, it does strengthen the view that local Aβ deposition plays a significant role.     
 
In terms of cognition, the precuneus is involved in a range of integrative cognitive 
functions in healthy adults, including episodic memory retrieval, self-processing, and 
visuospatial imagery, amongst others [31]. There is a body of evidence suggesting this 
region functions as the main `hub' in the default mode network (DMN), a network of 
intrinsic functional connectivity that becomes prominently synchronised during rest [45-
47]. Intrinsic functional connectivity in the DMN is abnormal in AD [48] and there is 
evidence to suggest this may be related to the degree of Aβ pathology [49]. Despite 
growing interest, the precise relationship between disruption to this region and the 
neurocognitive phenotype of Aβ is yet to emerge [50].      
 
The finding of similar differential associations between Aβ and P-tau in the lateral temporal 
regions is also consistent with the proposed model. Like the precuneus, this region is the 
site of early Aβ deposition, whereas tau-related pathology does not become prominent until 
relatively later in the disease [1, 32]. Aβ deposition in this region has been well 
documented using in vivo) imaging approaches [35], and global Aβ affinity has been 
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associated with structural atrophy in temporal neocortex [51]. In terms of the cognitive 
phenotype of DAT, hypometabolism and structural atrophy in this region has been 
associated with semantico-linguistic deficits [52]. Critically for the present study, local Aβ 
deposition in the superior temporal region has been specifically associated with the early 
disruption of language networks in DAT [21].  
 
It was expected that, while Aβ-related pathology would be most strongly associated with 
markers of pathology in neocortical regions, structuro-functional changes in the mesial 
temporal regions would be most strongly related to levels of P-tau. The selective 
association between Aβ and neocortex was consistent with the first prediction, however the 
mesial temporal hypotheses were not supported. A reason for this might be related to the 
technical challenges of imaging mesial temporal structures. Automated parcellation and 
segmentation offer efficient and reliable means of examining volumes and metabolic 
activity of specific brain structures. There is some evidence that manual segmentation 
might be optimal for delineating mesial temporal structures, especially in the context of 
structural atrophy [53]. Manual segmentation, however, is time-consuming, and there are as 
yet no universally accepted protocols for hippocampal tracing [54].  
 
Given that our sample is relatively young in terms of AD populations, it is possible that the 
development of tau-related pathology was not as advanced as the development of amyloid-
related pathology. This might further explain why relationships were observed for amyloid, 
but not tau. A clear direction for future research is to investigate this hypothesis across a 
range of ages and disease stages. Further, given the sample size we were unable to 
explicitly model the effects of relevant comorbidities (such as vascular burden, cognitive 
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function, and treatment status). Future research should confirm out findings in larger 
cohorts which allow for statistical modelling of these factors. 
 
Only the relationship between amyloid-pathology and hypometabolism in the precuneus 
survived when only participants with ‘abnormal’ CSF Aβ concentrations were included in 
the analysis. The smaller number of participants in this sub-analysis (only 29 of the total 
sample of 39) raises the question of inadequate statistical power. Future, well-powered 
studies are required to fully confirm these findings while taking diagnosis CSF status into 
account. It is important to note, however, that the development of AD biomarkers is an 
insidious process that might begin decades before a clinical diagnosis is warranted [55]. For 
example, Braak and Del Tredici [56] have documented the accumulation of AD pathology 
as early as the first decades of life. In previous work, we have shown differential 
relationships between CSF biomarkers and cognition in patients with mild cognitive 
impairment [7]. As such, it might be more ecologically valid to consider the effects of CSF 
biomarkers across a range of clinical stages.  
 
Hypometabolism in the mesial temporal regions is often difficult to identify [57]. One 
reason for this is the partial volume effect (PVE), which occurs when signal from a small 
structure is underestimated because voxels within it overlap more than one tissue class [58]. 
This effect occurs for structures smaller than two times the full-width half maximum 
(FWHM) of the scanner resolution, and is especially pronounced for GM structures 
adjacent to CSF spaces, such as the hippocampus [59]. While methods for correcting for 
PVE are available, they involve potential degradation of the data and can produce 
physiologically implausible results in the context of progressive atrophy [60].  
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Taken together, these findings support the proposed preferential association between 
pathological processes in AD and their topological distribution in the brain. The finding 
that hypometabolism and structural atrophy in the precuneus and lateral temporal regions 
were associated with Aβ but not P-tau supports the hypothesis that these two pathologies 
exert differential influence on neocortical regions. A limitation of this study was that it did 
not include healthy participants. An important task for future research will be to examine 
the relationships between biomarkers and cortical thickness measurements to ensure they 
are markers of pathological status, and are not otherwise related to brain structure and 
function. Cognitive markers were not evaluated as part of this study, as the primary focus 
was on the relationship between biomarkers and structuro-functional changes. This is an 
important limitation, and future work is necessary to examine the relationship between 
preferential biomarker changes and cognition. Although cognition was not directly 
evaluated in this study, these findings lend support to the hypothesis of dissociation 
between the two pathological processes in AD and their effects on the neurocognitive 
phenotype.  
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Tables 
Table 1. Sample characteristics 
 Mean 95% CI Range 
Demographics    
   Age (Years) 70 68 - 73 57 - 83 
   MMSE (Total) 20 19 - 21 14 - 29 
   ADAS-Cog (Total) 20 17 - 22 7 - 31 
CSF Biomarkers    
   P-tau (pg/ml) 86 75 - 96 27-175 
   T-tau (pg/ml) 940 806 - 1075 192 - 1962 
   Aβ1-42 (pg/ml) 481 413 - 549 224 - 1332 
N = 39 (22 males, 17 females). MMSE = Mini Mental Status Examination, ADAS-Cog = 
Alzheimer’s Disease Assessment Scale – Cognitive 
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Table 2. Descriptive data for the study sample 
 Mean [95% CI] 
 Structural volumetrics FDG-PET uptake 
Prefrontal 2.38 [2.33, 2.42] 1.14 [1.11, 1.17] 
Orbitofrontal 2.36 [ 2.31, 2.42] 1.03 [1.00, 1.05] 
Precuneus 2.03 [1.97, 2.10] 1.12 [1.07, 1.17] 
Lateral Temporal 2.47 [2.41, 2.52] 0.93 [0.90, 0.96] 
Anterior Cingulate 
Cortex 
2.72 [2.65, 2.80] 0.97 [0.95, 0.99] 
Entorhinal Cortex 2.77 [2.63, 2.90] 0.68 [0.65, 0.70] 
Hippocampus 
3063.78 [2866.78, 
3261.37] 
0.81 [0.79, 0.84] 
Note: Structural volumetrics are presented in millimetres (mm) for all measures, 
except for the hippocampus which is presented in millimetres cubed (mm3). 
FDG-PET uptake values are normalised to the cerebellum.  
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Figures 
 
Figure 1.  Specific FreeSurfer regions of interest. The FreeSurfer ROIs are given as the standard 
label names used in the software.  
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Figure 2.  Partial correlation between CSF biomarkers and structural volumetrics in specific 
regions. Only the precuneus (p = .01) and lateral temporal (p = .01) regions were correlated with 
Aβ, while no regions were correlated with P-tau. Asterisk indicate correlations that are statistically 
significant at p < .05 (FDR corrected). 
 
- 22 - 
Figure 3.  Partial correlation between CSF biomarkers and FDG-PET uptake in specific regions. 
Only the precuneus (p = .02) and lateral temporal regions (p = .02) were correlated with Aβ, while 
no regions were correlated with P-tau. Asterisk indicate correlations that are statistically significant 
at p < .05 (FDR corrected). 
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Figure 4.  Partial correlation between CSF total tau, FDG-PET uptake, and structural volumetrics 
in specific regions. No relationships were statistically significant at the p < .05 level (FDR 
corrected). 
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